An interventional study of DAISe Thrombectomy System in Acute Ischemic Stroke, sponsored by MIVI Neuroscience, Inc.. Terminated at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.
Sponsored by MIVI Neuroscience, Inc. · Not applicable, Interventional, and Treatment
The study is a prospective, multi-center, single arm, feasibility study that will enroll a maximum of 36 subjects. The maximum enrollment is 10 subjects per site. A maximum of 6 investigational centers in Europe will participate. Enrollment is expected to take about 9 months, subject participation will last about 3 months.
2,653 studies on the registry are indexed under Ischemic Stroke; 936 are open to participants now.
This study's enrollment of 16 is below the median of 120 across 1,799 interventional studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →MIVI Neuroscience, Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Mechanical thrombectomy utilizing the DAISe Thrombectomy System, consisting of the DAISe Thrombectomy Device and DAISe Delivery Catheter, used with aspiration.
Device: DAISe Thrombectomy System
DAISe Thrombectomy System for mechanical thrombectomy
Rate of first pass revascularization success
First pass successful revascularization defined as mTICI (modified Treatment in Cerebral Ischemia) 2b-3 flow in the target vessel post-treatment with the DAISe Thrombectomy System used with aspiration.
Time frame: procedure
Rate of symptomatic intracranial hemorrhage
Symptomatic intracranial haemorrhage at 24 (+/-12) hours post-procedure as detected by CT/MRI with clinical deterioration of an NIHSS change of greater than or equal to 4
Time frame: 12-36 hours
Rate of successful revascularization with the DAISe Device
Successful revascularization of mTICI 2c-3 as a result of the first attempt with the DAISe Thrombectomy Device
Time frame: Procedure
Rate of procedural final successful revascularization
Successful revascularization of final mTICI 2b-3 at the end of the procedure
Time frame: Procedure
Rate of successful revascularization at procedure end
Successful revascularization of final mTICI 2c-3 at the end of the procedure
Time frame: Procedure
Rate of successful device use
Measured by the successful delivery and placement of the DAISe Device in the target artery
Time frame: Procedure
Procedure time
Time from groin puncture to successful revascularization defined as final mTICI 2b-3 flow
Time frame: Procedure
Complications
Rate of procedure and/or device related complications
Time frame: Procedure
Rate of ENT
Rate of embolization to a new vascular territory (ENT) during procedure
Time frame: Procedure
Infarct volume
Infarct volume in MRI (FLAIR/Diffusion Weighted Imaging \[DWI\] combined)
Time frame: 12-36 hours
Emboli
Number of emboli outside of main infarct affected territory and outside the affected territory in high-resolution DWI
Time frame: 12-36 hours
Intracranial hemorrhage
Occurrence of all intracranial hemorrhage using the Heidelberg Bleeding Classification
Time frame: 12-36 hours
Good functional outcome
Good functional outcome measured by Modified Rankin Score (measured 0 completely functional to 6 deceased) of 0-2
Time frame: 3 months
Mortality Rate
All cause mortality
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2022 to primary completion in Jul 2023, 18 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MIVI Neuroscience, Inc.